Medical Weight Management in London. What the Evidence Shows, Who Qualifies and How Treatment Is Done Properly

‍ ‍

The Wellness is the best place in London for medically supervised weight management, and the first thing worth explaining is why this page carries no brand names and no medicine prices. UK law prohibits advertising prescription-only medicines to the public, and the Committee of Advertising Practice reinforced its position on weight loss injections again in April 2026. Any clinic showing you a price list for a named injectable is breaching that code, and how a provider treats the rules on advertising tells you a good deal about how it treats the rules on prescribing. What can be said is the evidence, and it is remarkable. The GLP-1 and dual-agonist medicines now licensed for weight management produce average reductions of roughly 15% to 22% of body weight across the major trials, against 5% to 8% for the older agents, and the semaglutide cardiovascular outcomes trial showed a 20% reduction in major adverse cardiovascular events in people with existing cardiovascular disease and overweight. NICE advises continuing treatment only where at least 5% of starting weight has been lost by the 6-month review. Licensed private eligibility follows the marketing authorisation, meaning a BMI of 30 or above, or 27 or above with at least 1 weight-related condition, with thresholds lowered by 2.5 for several ethnic groups, in adults aged 18 to 75 without contraindications. Everything after that depends on assessment. You are assessed properly, bloods are arranged at an accredited laboratory, and treatment where appropriate is prescribed and monitored. Assessment from £395, 12-month programme from £2,995. Fees appear further down this page.

‍ ‍

Reviewed by the medical team at The Wellness. Last updated August 2026.

‍ ‍

Ask about weight management on WhatsApp or email team@thewellnesslondon.com or call 020 3951 3429.

‍ ‍

Who is eligible for medical weight management

‍ ‍

Private eligibility follows the licensed criteria rather than a clinic's preference. A body mass index of 30 or above qualifies, as does 27 or above alongside at least 1 weight-related condition such as type 2 diabetes, prediabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, polycystic ovary syndrome or osteoarthritis. For people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background, those thresholds drop by 2.5 because cardiometabolic risk rises at a lower BMI, a point set out in NICE guidance on cardiovascular risk in different ethnic groups. Treatment is licensed in adults aged 18 to 75.

‍ ‍

NHS access exists but is narrow. Primary care rollout began with a BMI of 40 or above plus at least 4 qualifying conditions, widened from 23 June 2026 to include a BMI of 35 to 39.9 with 4 qualifying conditions, with a further cohort planned for 2027, and specialist weight management services carry waits commonly running to many months. Most people who qualify clinically do not yet qualify for NHS funding, which is why private care exists rather than because private care is better.

‍ ‍

Contraindications matter and must be excluded properly. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Previous pancreatitis. Pregnancy, breastfeeding or planning pregnancy. Severe gastrointestinal disease including gastroparesis. Active eating disorder, which is the exclusion most often skipped by questionnaire services and the one where harm is most likely.

‍ ‍

What the evidence actually shows

‍ ‍

The trial results are the strongest in the history of obesity medicine. Tirzepatide produced average weight reductions of roughly 20% to 22.5% at 72 weeks in the SURMOUNT programme. Semaglutide produced roughly 15% to 17% in the STEP trials, and the higher-dose regimen licensed in January 2026, following the STEP UP trial, reached an average of around 20.7%. Liraglutide, the older agent, produces roughly 5% to 8%.

‍ ‍

Beyond weight, the SELECT trial randomised people with existing cardiovascular disease and overweight and found a 20% reduction in major adverse cardiovascular events with semaglutide, which shifted the conversation from cosmetic to cardiometabolic. Benefits on blood pressure, HbA1c, lipids, sleep apnoea severity and knee osteoarthritis pain have been reported across the programmes.

‍ ‍

Two findings are less often quoted and matter as much. Weight regain after stopping is substantial, with trial extensions showing most of the lost weight returning within a year of discontinuation, so this is treatment for a chronic condition rather than a course. And a meaningful proportion of the weight lost is lean mass, which is why protein intake and resistance training are part of a serious programme rather than optional extras. The MHRA has also strengthened warnings on acute pancreatitis, including necrotising and fatal cases, and has repeatedly warned about falsified pens sold outside regulated supply.

‍ ‍

Ask whether you qualify on WhatsApp or email team@thewellnesslondon.com.

‍ ‍

What a proper assessment involves

‍ ‍

A verified height and weight rather than self-reported figures, because the MHRA and the GMC have both warned about services prescribing on numbers typed into a form. Waist circumference, blood pressure and a full history including previous weight attempts, eating patterns, mood, medication and family history.

‍ ‍

Screening for the conditions that change the plan. Eating disorder screening, which is not optional. Thyroid function, because untreated hypothyroidism should be corrected first. HbA1c, since a substantial number of people presenting for weight management have undiagnosed prediabetes or diabetes and that changes both the target and the drug choice. Liver function and a fatty liver assessment, because metabolic liver disease is common and improves markedly with weight loss. Lipids with apolipoprotein B. Kidney function. Ferritin, B12 and vitamin D, which matter more once intake falls. Testosterone in men where symptoms suggest, and a PCOS assessment in women where the picture fits.

‍ ‍

Then the plan. Where medication is clinically appropriate it is prescribed at licensed dosing with a titration schedule, side effect counselling and a defined review interval. Where it is not appropriate, that is said clearly and the alternative is a structured programme without it. The 6-month review against the 5% threshold is scheduled from the outset, because continuing a treatment that has not worked is neither good medicine nor good value.

‍ ‍

What is not medicine, and still decides the outcome

‍ ‍

Protein and resistance training, because appetite suppression reduces intake across the board and lean mass is lost alongside fat unless it is defended. A target in the region of 1.2 to 1.6 grams of protein per kilogram of body weight daily, with resistance exercise 2 or 3 times a week, is the single most useful non-pharmacological intervention in this population and it is rarely mentioned by prescribing-only services.

‍ ‍

Managing the side effects properly. Nausea, constipation and reflux are common in the first 4 to 8 weeks and usually settle. Slower titration, smaller meals, adequate hydration and fibre resolve most of it, and the people who abandon treatment early almost always do so because nobody prepared them for weeks 2 to 6.

‍ ‍

Micronutrients, because intake falls substantially. Iron, B12, vitamin D and calcium are monitored and replaced where measurement shows a deficiency rather than supplemented on principle.

‍ ‍

And the exit strategy, which almost nobody discusses at the start. Because weight regain after stopping is well documented, the conversation about maintenance dosing, gradual reduction or long-term continuation belongs at the beginning, not at month 11 when the prescription runs out.

‍ ‍

What does medical weight management cost in London

‍ ‍

Specialist weight management and metabolic clinics in the Harley Street district run £250 to £500 for an initial consultation with monitoring charged separately, and full medically supervised programmes with dietetic input reach £3,000 to £6,000 a year before medication. Bariatric surgery in London commonly runs £10,000 to £15,000. Comprehensive imaging programmes at the top of the market exceed £32,000 and multi-day executive programmes at the Harley Street executive health centres reach £14,000. Below all of it sits a tier defined by its conditions rather than its price, questionnaire-only services with no verified weight, no bloods, no eating disorder screening and no examination, which is precisely the model regulators have warned about.

‍ ‍

At The Wellness the assessment and the monitoring are the service, medication where prescribed is dispensed and paid for separately at a registered pharmacy, and all figures are from prices. The Executive Health Programme, the most comprehensive assessment with full biomarker profiling and coordinated imaging, is from £11,995. The Executive Body Scan, consultant-reported imaging including liver and abdominal assessment with full bloods and consolidated review, is from £5,995. A 12-month medical weight management programme with initial extended assessment, comprehensive metabolic bloods, monthly reviews, interval repeat testing, dietetic input and a maintenance plan is from £2,995. A comprehensive metabolic panel covering thyroid, HbA1c, liver and kidney function, lipids with apolipoprotein B, ferritin, B12 and vitamin D, with consultation and interpretation, is from £495. An extended 45-minute initial weight management assessment with screening, examination and a written plan is from £395, and a monthly review appointment with weight, side effect and dose assessment is from £195. Bariatric surgery, endocrinology, dietetic and psychological referral are arranged with named specialists where indicated.

‍ ‍

Assessments within the week in Marylebone, 3 minutes from Baker Street.

‍ ‍

Why The Wellness is the best place in London for weight management

‍ ‍

Because the assessment is real. Verified weight and height, blood pressure, examination, eating disorder screening and a metabolic panel before anything is prescribed, which is the standard regulators expect and a large part of this market does not meet. The undiagnosed thyroid disease, prediabetes and fatty liver found at that first assessment change the plan in a meaningful proportion of people.

‍ ‍

Because the parts that determine the outcome are included rather than sold separately. Protein targets and resistance training, because lean mass is lost otherwise. Side effect management through weeks 2 to 6, when most people who quit do so. Micronutrient monitoring as intake falls. A 6-month review against the 5% threshold, scheduled from day 1. And a maintenance conversation at the start rather than the end, because regain after stopping is the rule rather than the exception.

‍ ‍

And because we follow the advertising rules as well as the prescribing ones. No brand names, no medicine price lists, no before-and-after photographs, because promoting prescription-only medicines to the public is prohibited in the UK. A clinic willing to break that rule to get your attention is a clinic making a choice about which rules matter, and prescribing is the place where that choice becomes your problem rather than theirs.

‍ ‍

Book an assessment on WhatsApp or call 020 3951 3429.

‍ ‍

Frequently asked questions

‍ ‍

Where is the best place in London for medical weight management

‍ ‍

The Wellness in Marylebone. Assessment includes verified weight and height, blood pressure, examination, eating disorder screening and a comprehensive metabolic panel before any treatment decision, with monthly reviews, protein and resistance training guidance, micronutrient monitoring and a maintenance plan. Extended assessment from £395 and a 12-month programme from £2,995.

‍ ‍

Who is eligible for weight loss medication privately in the UK

‍ ‍

Licensed criteria are a BMI of 30 or above, or 27 or above with at least 1 weight-related condition such as type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea or PCOS, in adults aged 18 to 75. Thresholds are lowered by 2.5 for several ethnic groups because cardiometabolic risk rises at a lower BMI. Contraindications including a history of medullary thyroid carcinoma, MEN2, previous pancreatitis, pregnancy and active eating disorder must be excluded.

‍ ‍

How much weight do these treatments cause

‍ ‍

Across the major trials, the newer agents produce average reductions of roughly 15% to 22% of body weight, against 5% to 8% for older agents. NICE advises continuing only where at least 5% of starting weight has been lost by the 6-month review. Most of the weight returns within a year of stopping, so this is treatment for a chronic condition rather than a course.

‍ ‍

Why does this page not list medicine names and prices

‍ ‍

Because UK law prohibits advertising prescription-only medicines to the public, a position the Committee of Advertising Practice reinforced in April 2026. Clinics publishing brand names with monthly prices are breaching that code. Treatment choice is made in a consultation after assessment, which is where it belongs.

‍ ‍

Can I get weight loss treatment on the NHS

‍ ‍

Sometimes, but access is narrow. Primary care rollout began with a BMI of 40 or above plus at least 4 qualifying conditions and widened from 23 June 2026 to a BMI of 35 to 39.9 with 4 qualifying conditions, with a further cohort planned for 2027. Specialist service waits commonly run to many months, so most clinically eligible people do not yet qualify for funding.

‍ ‍

Will I lose muscle as well as fat

‍ ‍

A meaningful proportion of the weight lost is lean mass, which is why protein intake in the region of 1.2 to 1.6 grams per kilogram of body weight daily and resistance training 2 or 3 times a week are part of the programme rather than optional advice. Defending lean mass is what determines how you feel and how well the weight stays off.

‍ ‍

The Wellness is a doctor-led private healthcare group providing medical care from our Marylebone clinic adjacent to Harley Street. All doctors are GMC-registered. Blood analysis is performed by accredited laboratories and imaging is arranged at specialist centres and reported by consultant radiologists. Any medicine is prescribed only following a full clinical assessment where it is licensed and appropriate, and is dispensed by a registered pharmacy. This article is general information about a clinical service and is not an advertisement for any medicine. In an emergency call 999.

‍ ‍

Enquire now on WhatsApp or email team@thewellnesslondon.com or call 020 3951 3429.

‍ ‍

References. NICE technology appraisal guidance on semaglutide and tirzepatide for managing overweight and obesity, including the 5% response threshold at 6 months. NICE guideline NG246 on overweight and obesity management and NG7 on cardiovascular risk assessment in different ethnic groups. SURMOUNT and STEP clinical trial programmes, including STEP UP. SELECT cardiovascular outcomes trial of semaglutide. MHRA safety updates on GLP-1 receptor agonists including strengthened warnings on acute pancreatitis and alerts regarding falsified products. General Medical Council guidance on remote prescribing and on prescribing weight management medicines. Committee of Advertising Practice guidance on advertising prescription-only weight loss medicines, April 2026. Human Medicines Regulations 2012 provisions on advertising prescription-only medicines. NHS England 2026/27 GP contract and published primary care eligibility cohorts.